Calithera Biosciences, Inc.·4

Jan 22, 5:56 PM ET

Orford Keith 4

4 · Calithera Biosciences, Inc. · Filed Jan 22, 2020

Insider Transaction Report

Form 4
Period: 2020-01-17
Orford Keith
SR. VP, CLINICAL DEVELOPMENT
Transactions
  • Award

    Stock Option (Right to Buy)

    2020-01-17+140,000140,000 total
    Exercise: $7.41Exp: 2030-01-17Common Stock (140,000 underlying)
Footnotes (1)
  • [F1]One-fourth (1/4th) of the Option vests one year after January 17, 2020; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION